Sanofi Pasteur Inaugurates High Tech Vaccine Production Facility

Sanofi Pasteur (Lyon, France), the vaccines division of the Sanofi-Aventis Group, has announced the inauguration of a high-tech vaccine production facility in France to respond to soaring demand worldwide.

Sanofi Pasteur (Lyon, France), the vaccines division of the Sanofi-Aventis Group, has announced the inauguration of a high-tech vaccine production facility in France to respond to soaring demand worldwide. This new €100-million facility, located in Val de Reuil, France, incorporates the latest technology to produce vaccines that meet the highest standards of quality. It is a part of €600-million investments undertaken by Sanofi Pasteur in France between 2005 and 2008.

The new highly automated facility can produce vaccines against 20 diseases. It is designed to be ready to switch to pandemic influenza vaccine in the event of a human pandemic influenza, once a pandemic influenza strain is identified by the World Health Organization.

Construction of the 7,800 square-meter building began in 2006. It is projected to be operational by the end of 2008, upon certification by health authorities. The facility is scaled to fill 200 million syringes and vials per year, increasing the current capacity at the site by two-fold.

Sanofi Pasteur release (PDF)